Merck Collaborates with Foghorn to Develop Oncology Therapies Against Transcription Factor Target
Shots:
- Foghorn will receive an upfront- development- regulatory and commercial milestones totaling up to $425M as well as royalties on sales of any approved therapy emerges from the collaboration
- Merck to get an exclusive global right to develop and commercialize drugs targeting dysregulation of a single transcription factor. The collaboration will deploy Foghorn’s Gene Traffic Control platform to discover and develop novel therapies against a transcription factor target
- Utilizing its Gene Traffic Control platform- Foghorn is interrogating and drugging the chromatin regulatory system. The company is advancing ~10 small molecule and protein degrader programs across multiple cancer indications and expects to file an IND for its first program in H2’20
Click here to read full press release/ article
Ref: PRNewswire | Image: Merck
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com